iOmx re­fu­els with $75M+ on its search for im­mune check­point tar­gets on tu­mor cells

While a big chunk of on­col­o­gy re­search is fo­cused on tar­get­ing T-cell reg­u­la­tors to stamp out can­cer, iOmx Ther­a­peu­tics is hom­ing in on im­mune check­point …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER